Febuxostat

Rheumatologists report largely adhering to American College of Rheumatology guidelines for gout management, but show notable divergence with the recommended dosages of urate-lowering therapies, according to survey data.

Allopurinol and febuxostat were both associated with lower all-cause mortality when used by adults undergoing hemodialysis in Japan; allopurinol also lowered risk of death from CVD events, according to study data.

The risk for gout flare when initiating urate lowering therapy varies based on the drug and dosing strategy used, according to a systematic review and network meta-analysis published in Arthritis Care & Research.

Starting urate lowering therapy during a gout flare does not impact the flare’s severity, duration or risk for recurrence over the following month, according to a systematic review and meta-analysis.

A more intensive serum urate target is difficult to achieve with oral urate-lowering therapy, compared with a standard target of 0.3 mmol/L, and fails to improve bone erosion scores in patients with erosive gout, according to a study.

Allopurinol is noninferior to febuxostat for gout when dosed appropriately as part of a treat-to-target strategy, according to data presented at ACR Convergence 2021.

ATLANTA — The 2019 ACR gout guidelines call for treating patients to a target serum urate level of 6 mg/dL, a marked departure from the 2012 document, according to speakers at ACR/ARP 2019.

SAN DIEGO — Prolonged adherence to urate-lowering therapies is critical for patients to manage gout, yet only a fraction of patients receive the appropriate therapy, according to a presentation at the 2019 Congress of Clinical Rheumatology West.